about
The evolving Gleason grading systemCentral role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic interventionShear wave elastography for detection of prostate cancer: a preliminary study.Outcomes and trends of prostate biopsy for prostate cancer in Chinese men from 2003 to 2011.Standardization of Gleason grading among 337 European pathologists.Prostate cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010.Prostate cancer: towards the standardization and synthesis of morphology, genetics, and prognosis.On the relationship between tumor structure and complexity of the spatial distribution of cancer cell nuclei: a fractal geometrical model of prostate carcinoma.From Gleason to International Society of Urological Pathology (ISUP) grading of prostate cancer.Does true Gleason pattern 3 merit its cancer descriptor?Increased SNAIL expression and low syndecan levels are associated with high Gleason grade in prostate cancerGleason inflation 1998-2011: a registry study of 97,168 men.Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS).Ductal and Acinar Adenocarcinoma of Prostate: Morphological and Immunohistochemical Characterization.The reasons behind variation in Gleason grading of prostatic biopsies: areas of agreement and misconception among 266 European pathologists.Efficiency of pretreatment risk stratification systems for prostate cancer in a Japanese population treated with radical prostatectomy.Transrectal quantitative shear wave elastography in the detection and characterisation of prostate cancer.Significance of Gleason grading of low-grade carcinoma of the prostate with therapeutic option of active surveillance.Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men.Apparent diffusion coefficient ratio correlates significantly with prostate cancer gleason score at final pathology.Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection.
P2860
Q26752936-CBF858BC-6D4B-4D1B-BDBD-0E8E5CEAD6F0Q26864839-81674780-DCCF-4C65-A2FE-4FD0ADB8253EQ33620198-0C237220-37BD-4392-86E4-B9655FEB3365Q34493929-66D1462B-4167-40EB-94C6-722C3EF46144Q34512822-85736656-B97F-440B-B0F7-C3379F45C255Q35439944-6AFACC90-4A1B-4823-B80D-FB8F240172DBQ37972696-2786923D-3662-4D11-951A-C23646184E0DQ38302346-D42E8547-FA0B-4F4A-9A77-4BE720B5CF4DQ38841964-EA6265C3-432C-41A1-AE83-F068ACDB9D82Q38928930-4C47F992-5F5F-4CAB-AB46-2AB504CC0377Q39034367-59ABFA74-D32C-4ACB-97A4-BFFA38033539Q39199397-9D639CEB-2D47-46EB-B260-F0946C7AAC6FQ40865231-8C921039-8DD0-4513-B3B5-1F16E4FD1225Q42591821-2AEF8DB8-2789-44CA-9A59-84446476898FQ44345074-FC81B6CB-339D-4791-95E7-5DEDFFD3AC6FQ44373070-825A7E08-707A-481B-BDFC-60F3F4205A65Q45827626-8555640E-AC12-47A9-A2F9-B01DC90BFA81Q45835286-F5D7A4EF-D23A-4C57-89C0-18E5E6D06EE3Q48021100-A7B4AA44-8828-4010-89CD-8CD0D73E0AB8Q51010281-A42CDB9C-4629-47D3-9FD3-4A7B5AD0A93AQ53425237-5EE2CF31-4263-44F9-A80C-DD37F9B4AA59
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Gleason grading: past, present and future.
@en
Gleason grading: past, present and future.
@nl
type
label
Gleason grading: past, present and future.
@en
Gleason grading: past, present and future.
@nl
prefLabel
Gleason grading: past, present and future.
@en
Gleason grading: past, present and future.
@nl
P2093
P2860
P1433
P1476
Gleason grading: past, present and future.
@en
P2093
Andrew J Evans
Brett Delahunt
John R Srigley
Rose J Miller
P2860
P356
10.1111/J.1365-2559.2011.04003.X
P577
2012-01-01T00:00:00Z